Standout Papers

Immediate Impact

1 from Science/Nature 66 standout
Sub-graph 1 of 21

Citing Papers

Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
2025 Standout
The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
2022 Standout
2 intermediate papers

Works of Michaela Mattheus being referenced

How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial
2024
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 Standout
and 3 more

Author Peers

Author Last Decade Papers Cites
Michaela Mattheus 11062 4754 4439 80 13.1k
Odd Erik Johansen 14296 6166 5659 118 17.1k
Stefan Hantel 9082 4555 3893 62 13.3k
Ofri Mosenzon 12734 4655 5245 140 15.1k
Hans J. Woerle 11126 5444 5008 88 12.9k
Maximilian von Eynatten 7968 3409 3119 114 10.7k
Mehul Desai 7621 3333 3202 49 9.2k
Greg Fulcher 7548 3312 2847 62 9.2k
David Fitchett 12416 6610 5125 198 18.0k
Avivit Cahn 7371 2872 3007 111 8.8k
David Z.I. Cherney 10214 4801 3528 323 14.1k

All Works

Loading papers...

Rankless by CCL
2026